{
    "clinical_study": {
        "@rank": "114283", 
        "arm_group": [
            {
                "arm_group_label": "MK-3102", 
                "arm_group_type": "Experimental", 
                "description": "Participants receive an MK-3102 25 mg capsule once weekly and glimepiride placebo tablet(s) once daily, for 54 weeks."
            }, 
            {
                "arm_group_label": "Glimepiride", 
                "arm_group_type": "Active Comparator", 
                "description": "Participants receive glimepiride tablet(s) (1 mg or 2 mg, maximum dose 6 mg/day) once daily and an MK-3102 placebo capsule once weekly, for 54 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "This trial will assess the safety and efficacy of MK-3102 compared with the sulfonylurea,\n      glimepiride, in Type 2 diabetes mellitus participants who are metformin intolerant or who\n      have a contraindication to the use of metformin."
        }, 
        "brief_title": "A Study to Evaluate the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus for Whom Metformin is Inappropriate (MK-3102-027)", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosed with Type 2 diabetes mellitus\n\n          -  Have intolerability to metformin \u22651000 mg/day or have a contraindication to the use\n             of metformin\n\n          -  Females of reproductive potential agree to remain abstinent or use or have their\n             partner use 2 acceptable methods of birth control\n\n        Exclusion Criteria:\n\n          -  History of type 1 diabetes mellitus or a history of ketoacidosis or assessed by the\n             investigator as possibly having type 1 diabetes\n\n          -  Has been treated with:\n\n               1. A thiazolidinedione (TZD) within 4 months of study participation, or\n\n               2. A glucagon-like peptide-1 (GLP-1) receptor mimetic or agonist (such as exenatide\n                  or liraglutide) within 6 months of study participation, or\n\n               3. Insulin within 12 weeks prior to study participation, or\n\n               4. Dual antihyperglycemic agent (AHA) therapy within 12 weeks of study\n                  participation (4 months if a component of the dual AHA therapy was a TZD)\n\n               5. MK-3102 at any time prior to study participation\n\n          -  On a weight loss program and is not in the maintenance phase; has started a weight\n             loss medication in the past 6 months; or has undergone bariatric surgery within 12\n             months prior to study participation\n\n          -  Medical history of active liver disease (other than non-alcoholic hepatic steatosis),\n             including chronic active hepatitis B or C, primary biliary cirrhosis, or symptomatic\n             gallbladder disease\n\n          -  Human immunodeficiency virus\n\n          -  New or worsening coronary heart disease, congestive heart failure, myocardial\n             infarction, unstable angina, coronary artery intervention, stroke or transient\n             ischemic neurological disorder within the past 3 months\n\n          -  History of malignancy \u22645 years prior to study participation except for adequately\n             treated basal cell or squamous cell skin cancer, or in situ cervical cancer\n\n          -  Clinically important hematological disorder (such as aplastic anemia,\n             myeloproliferative or myelodysplastic syndromes, thrombocytopenia)\n\n          -  Pregnant or breast-feeding, or is expecting to conceive or donate eggs during the\n             trial, including 21 days following the last dose of study drug"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "65", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01863667", 
            "org_study_id": "3102-027", 
            "secondary_id": "2013-000301-23"
        }, 
        "intervention": [
            {
                "arm_group_label": "MK-3102", 
                "intervention_name": "MK-3102", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Glimepiride", 
                "intervention_name": "Glimepiride", 
                "intervention_type": "Drug", 
                "other_name": [
                    "AMARYL\u00ae", 
                    "GLIMY"
                ]
            }, 
            {
                "arm_group_label": "Glimepiride", 
                "intervention_name": "MK-3102 Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "MK-3102", 
                "intervention_name": "Glimepiride Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glimepiride", 
                "Metformin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 29, 2014", 
        "number_of_arms": "2", 
        "official_title": "A Phase III, Multicenter, Double-Blind, Randomized Trial to Evaluate the Safety and Efficacy of MK-3102 Compared With Glimepiride in Subjects With Type 2 Diabetes Mellitus For Whom Metformin is Inappropriate Due to Intolerance or Contraindication", 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Change from Baseline in A1C at Week 54", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 54"
            }, 
            {
                "measure": "Percentage of Participants Who Experienced at Least One Adverse Event", 
                "safety_issue": "Yes", 
                "time_frame": "57 weeks"
            }, 
            {
                "measure": "Percentage of Participants Who Discontinued from the Study Due to an Adverse Event", 
                "safety_issue": "Yes", 
                "time_frame": "54 weeks"
            }
        ], 
        "removed_countries": {
            "country": [
                "United States", 
                "Austria", 
                "Russian Federation", 
                "Belgium", 
                "Bulgaria", 
                "Estonia", 
                "Germany", 
                "Hungary", 
                "Italy", 
                "Poland", 
                "Serbia", 
                "Slovakia", 
                "Spain", 
                "Ukraine"
            ]
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01863667"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from Baseline in Fasting Plasma Glucose (FPG) at Week 54", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 54"
            }, 
            {
                "measure": "Percentage of Participants Achieving an A1C Goal <7.0% and <6.5% After 54 weeks of Treatment", 
                "safety_issue": "No", 
                "time_frame": "54 weeks"
            }, 
            {
                "measure": "Percentage of Participants Meeting the Composite Endpoint of an A1C Decrease >0.5%, No Symptomatic Hypoglycemia, and No Body Weight Gain after 54 Weeks of Treatment", 
                "safety_issue": "No", 
                "time_frame": "54 weeks"
            }, 
            {
                "measure": "Percentage of Participants with an Adverse Event of Symptomatic Hypoglycemia", 
                "safety_issue": "Yes", 
                "time_frame": "54 weeks"
            }, 
            {
                "measure": "Change from Baseline in Body Weight at Week 54", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and Week 54"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}